Tongue Carcinoma Clinical Trial
Official title:
Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
The purpose of this study is to see how the brain re-learns to control the tongue in
speaking and swallowing when either portions of the tongue have been removed, or when the
tongue has been treated with radiation, in order to treat cancer. We hope the results of
this study will help us to improve healing for patients who are being treated for cancer of
the tongue.
When patients with cancer of the tongue are treated by removing parts of the tongue
(surgery) or by destroying the cancer with radiation to the tongue, they have significant
difficulty speaking and swallowing after such treatments. At this time, patients who have
been treated for cancer of the tongue re-learn speaking and swallowing through exercises
taught by a speech pathologist.
What is needed is information on how the brain re-learns to control speaking and swallowing
so that we can help these patients re-learn faster after their treatments.
The purpose of this investigation is to determine cortical mechanisms of adaptation to
surgical or radiation treatment to the tongue. This study will use a non-invasive imaging
technique, Functional Magnetic Resonance Imaging (fMRI), to investigate cortical responses
to partial glossectomy or radiation therapy for treatment of a tongue malignancy. Patients
with Stage I-IV (AJCC) malignancies of the tongue who are treated with surgery and or
radiation therapy will be imaged using fMRI pre-operatively and at approximately six months
postoperatively.
Patterns of brain activity from the fMRI studies will be compared with matched healthy
control subjects. The results of this investigation will provide needed information on both
central and peripheral mechanisms of adaptation.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02254278 -
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT01256385 -
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
|
Phase 2 | |
Recruiting |
NCT04870762 -
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
|
Phase 2 | |
Terminated |
NCT02196168 -
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02007200 -
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
|
Phase 2 | |
Completed |
NCT00458978 -
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT01254617 -
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
|
Phase 1 | |
Active, not recruiting |
NCT00588770 -
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 3 | |
Completed |
NCT01175980 -
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
Terminated |
NCT02068157 -
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
|
Phase 2 |